Kyorin pact another arrow in Daiichi Sankyo's South American quiver
This article was originally published in Scrip
In another move to build up its business in major emerging markets, Daiichi Sankyo has acquired exclusive development and commercialisation rights in Brazil to Kyorin Pharmaceutical's overactive bladder therapy imidafenacin.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.